Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes

Silvio E Inzucchi

Endocrinology and Metabolism Clinics of North America 2007, 36 Suppl 2 Incretin: 2-17

No abstract text is available yet for this article.

Read this article (multiple options)

Find additional links »

You are not logged in. Sign Up or Log In to join the discussion.

Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. Matteo Monami, Francesco Cremasco, Caterina Lamanna, Niccolò Marchionni, Edoardo Mannucci Diabetes/metabolism Research and Reviews 2011, 27 (4): 362-72

Current and emerging therapies: an overview of incretin-based therapy in the management of type 2 diabetes. Richard E Pratley Journal of the American Academy of Nurse Practitioners 2008, 20 Suppl 1: 7-11

Pharmacological management of type 2 diabetes mellitus: an update. Samer El-Kaissi, Suphia Sherbeeni Current Diabetes Reviews 2011, 7 (6): 392-405

Diabetes mellitus. Medication update. Mark Slagle Southern Medical Journal 2002, 95 (1): 50-5

[Tough glucose reduction necessary in newly diagnosed diabetes]. Mikael Rydén Läkartidningen 2010 November 10, 107 (45): 2810-4

Seeking sweet relief for diabetes. Alan Dove Nature Biotechnology 2002, 20 (10): 977-81

Beyond glycemic control: the effects of incretin hormones in type 2 diabetes. Catherine L Martin Diabetes Educator 2008, 34 Suppl 3: 66S-72S

Which oral agent to use when metformin is no longer effective? Michael Bannon QJM: Monthly Journal of the Association of Physicians 2011, 104 (3): 183-4

Use Read by QxMD to access full text via your institution or open access sources.

Read also provides personalized recommendations to keep you up to date in your field.

Existing User

New to Read

Read